A selective vasodilator targeting pericytes reverses capillary no-reflow in ischaemia–reperfusion injury

Q: What does this research mean for the field?

A capillary-selective vasodilator that directly inhibits smooth muscle myosin in pericytes rapidly and durably reverses established capillary no-reflow in animal models of ischaemia-reperfusion injury. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Irene Fernández-Ruíz

doi:10.1038/s41569-026-01364-x

November 9, 2026Nature Reviews Cardiology

A selective vasodilator targeting pericytes reverses capillary no-reflow in ischaemia–reperfusion injury

View at Publisher

Ask AI

Bookmark

Share

Key result

Capillary-selective pericyte vasodilator rapidly and durably reverses established ischemia-reperfusion no-reflow in animal models.

Why the study?

Does a capillary-selective vasodilator directly inhibiting smooth muscle myosin in pericytes reverse established capillary no-reflow in animal models of ischaemia–reperfusion injury?

Key Points

To determine whether a selective vasodilator targeting pericyte smooth muscle myosin can reverse established capillary no-reflow following ischaemia–reperfusion injury.
Evaluated a novel capillary-selective vasodilator designed to directly inhibit smooth muscle myosin in pericytes.
Tested the therapeutic agent in animal models exhibiting established microvascular capillary no-reflow following ischaemia and reperfusion.
Direct inhibition of smooth muscle myosin in pericytes rapidly reversed established capillary no-reflow in animal models.
The microvascular dilation was durable over time, successfully restoring sustained capillary perfusion after ischaemia–reperfusion injury.

Structured PICO

Does a capillary-selective vasodilator directly inhibiting smooth muscle myosin in pericytes reverse established capillary no-reflow in animal models of ischaemia–reperfusion injury?

P

Population

Animal model with ischaemia–reperfusion injury and established capillary no-reflow

I

Intervention

Capillary-selective vasodilator directly inhibiting smooth muscle myosin in pericytes

O

Outcome

Reversal of established capillary no-reflowsurrogate

A new capillary-selective vasodilator that directly inhibits smooth muscle myosin in pericytes rapidly and durably reverses established capillary no-reflow in animal models of ischaemia–reperfusion injury.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Prompts first-in-human trials of pericyte myosin inhibition; leaves open translation to clinical outcomes in ischemia-reperfusion.

Abstract

Nature Reviews Cardiology - A new capillary-selective vasodilator that directly inhibits smooth muscle myosin in pericytes rapidly and durably reverses established capillary no-reflow in animal...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Irene Fernández-Ruíz (2026) studied this question. A capillary-selective vasodilator inhibiting smooth muscle myosin in pericytes rapidly and durably reversed established capillary no-reflow in animal models of ischemia-reperfusion injury.

synapsesocial.com/papers/6af354a85b67d29976ea0811 https://doi.org/10.1038/s41569-026-01364-x

View at Publisher

Ask AI

Bookmark

Share

A selective vasodilator targeting pericytes reverses capillary no-reflow in ischaemia–reperfusion injury

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

A selective vasodilator targeting pericytes reverses capillary no-reflow in ischaemia–reperfusion injury

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading